Fascinating that you connected these dots. There does appear to be a connection, agree. BioPete debunked his article pretty effectively, and so did the market, no damage sustained to the stock. What a piece of crapola he is, to attack the credibility of such a fine company whose accomplishments are so solid?
It's his job to offer a balanced view of the possibilities that a drug or device in this case may not be approved. Take off those ATRS tinted glasses and keep an open eye in this case to another point of view.